Merck & Co., Inc. (MRK)
Merck & Co., Inc. $MRK Stake Increased by AEGON ASSET MANAGEMENT UK Plc
AEGON ASSET MANAGEMENT UK Plc lifted its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 3.0% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,299,758 shares of the company's stock after purchasing an additional 37,433 shares during the period. Merck
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Merck (MRK) closed at $111.9, marking a -2.37% move from the previous day.
Will Lower Gardasil Sales Hurt MRK's Vaccines Sales in Q1 Earnings?
Gardasil's sharp sales slump in China and Japan puts Merck under pressure heading into Q1 earnings, as new vaccine Capvaxive gains momentum.
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study
Merck stock slides as Keytruda-based triplet therapy misses main goals in a late-stage study in first-line advanced renal cell carcinoma.
CPC Advisors LLC Increases Position in Merck & Co., Inc. $MRK
CPC Advisors LLC grew its holdings in Merck and Co., Inc. (NYSE: MRK) by 1,728.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 68,380 shares of the company's stock after buying an additional 64,641 shares during the period. CPC Advisors LLC's holdings in Merck and
MRK's sBLAs for Keytruda Combo in Bladder Cancer Get FDA Priority Tag
FDA grants priority review to Merck's sBLAs for Keytruda & Keytruda SC in combination with Pfizer's Padcev in cisplatin-eligible MIBC patients.
US FDA approves Merck's combination HIV treatment
The U.S. Food and Drug Administration approved Merck's once-daily, oral, combination regimen for HIV infections, the health regulator's website showed on Tuesday.
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Merck (MRK) stood at $117.1, denoting a -1.65% move from the preceding trading day.
Merck Secures EU Nod for RSV Antibody Enflonsia in Infants
MRK gains EU approval for Enflonsia to prevent RSV in infants during their first season.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
MRK's Keytruda, driving over half of its pharma sales, remains in focus as Q1 nears, with growth expected from new indications and strong uptake.
